JP2016535780A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016535780A5 JP2016535780A5 JP2016552432A JP2016552432A JP2016535780A5 JP 2016535780 A5 JP2016535780 A5 JP 2016535780A5 JP 2016552432 A JP2016552432 A JP 2016552432A JP 2016552432 A JP2016552432 A JP 2016552432A JP 2016535780 A5 JP2016535780 A5 JP 2016535780A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- patient
- ferric citrate
- kidney disease
- chronic kidney
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 20
- 229940124597 therapeutic agent Drugs 0.000 claims 20
- 229960002413 ferric citrate Drugs 0.000 claims 16
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 claims 16
- 208000020832 chronic kidney disease Diseases 0.000 claims 9
- 230000002411 adverse Effects 0.000 claims 8
- 230000000747 cardiac effect Effects 0.000 claims 8
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 claims 7
- 102100024802 Fibroblast growth factor 23 Human genes 0.000 claims 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 4
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 claims 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 2
- 229910052742 iron Inorganic materials 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 239000011574 phosphorus Substances 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 206010049418 Sudden Cardiac Death Diseases 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361899866P | 2013-11-04 | 2013-11-04 | |
| US61/899,866 | 2013-11-04 | ||
| PCT/US2014/063643 WO2015066593A1 (en) | 2013-11-04 | 2014-11-03 | Ferric citrate for reducing cardiac failure in chronic kidney disease patients |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019140640A Division JP6828100B2 (ja) | 2013-11-04 | 2019-07-31 | 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016535780A JP2016535780A (ja) | 2016-11-17 |
| JP2016535780A5 true JP2016535780A5 (enExample) | 2017-12-14 |
Family
ID=53005244
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552432A Pending JP2016535780A (ja) | 2013-11-04 | 2014-11-03 | 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄 |
| JP2019140640A Active JP6828100B2 (ja) | 2013-11-04 | 2019-07-31 | 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄 |
| JP2021007091A Pending JP2021073230A (ja) | 2013-11-04 | 2021-01-20 | 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019140640A Active JP6828100B2 (ja) | 2013-11-04 | 2019-07-31 | 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄 |
| JP2021007091A Pending JP2021073230A (ja) | 2013-11-04 | 2021-01-20 | 慢性腎臓病患者の心不全を軽減するためのクエン酸第二鉄 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20160256486A1 (enExample) |
| EP (2) | EP3747432A1 (enExample) |
| JP (3) | JP2016535780A (enExample) |
| KR (1) | KR102392441B1 (enExample) |
| CN (1) | CN105873583A (enExample) |
| AU (1) | AU2014341975A1 (enExample) |
| BR (1) | BR112016009901A8 (enExample) |
| CA (1) | CA2928200A1 (enExample) |
| EA (1) | EA201690926A1 (enExample) |
| HK (1) | HK1223031A1 (enExample) |
| IL (1) | IL245317A0 (enExample) |
| MX (1) | MX2016005734A (enExample) |
| SG (1) | SG11201603091QA (enExample) |
| TW (2) | TWI744215B (enExample) |
| WO (1) | WO2015066593A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140016438A (ko) | 2009-07-21 | 2014-02-07 | 케릭스 바이오파마슈티컬스 인코포레이티드 | 구연산철 투여형태 |
| ES2834485T3 (es) | 2013-06-05 | 2021-06-17 | Tricida Inc | Polímeros de unión a protones para administración oral |
| EP3157516A4 (en) | 2014-06-22 | 2017-12-13 | Dexcel Pharma Technologies Ltd. | Pharmaceutical compositions comprising ferric citrate and methods for the production thereof |
| MA41150B1 (fr) | 2014-12-10 | 2020-06-30 | Tricida Inc | Polymères de liaison aux protons pour administration orale |
| MA44875A (fr) | 2016-05-06 | 2019-03-13 | Tricida Inc | Compositions pour le traitement de troubles acido-basiques |
| IL273960B2 (en) | 2017-11-03 | 2025-08-01 | Tricida Inc | Nonabsorable compositions for use in treating or preventing metabolic acidosis |
| WO2020089227A1 (en) | 2018-10-29 | 2020-05-07 | Pharmacosmos Holding A/S | Treating iron deficiency with ferric carboxymaltose |
| EA202191858A1 (ru) * | 2019-06-12 | 2021-11-12 | Фармакосмос Холдинг А/С | Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий |
| TW202313072A (zh) * | 2021-05-27 | 2023-04-01 | 美商凱立克斯生物製藥股份有限公司 | 檸檬酸鐵之兒科調配物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE351366B (enExample) * | 1965-06-08 | 1972-11-27 | Teikoku Hormone Mfg Co Ltd | |
| US20050203169A1 (en) * | 2001-08-06 | 2005-09-15 | Moskowitz David W. | Methods and compositions for treating diseases associated with excesses in ACE |
| TWI335218B (en) | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
| US8093423B2 (en) * | 2003-02-19 | 2012-01-10 | Globoasia, Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same |
| EP2594551B1 (en) * | 2005-08-18 | 2025-02-19 | Panion & BF Biotech Inc. | Uses of pharmaceutical-grade ferric organic compounds |
| KR20080106506A (ko) * | 2006-01-30 | 2008-12-08 | 글로보아시아 엘엘씨 | 만성 신장병의 치료 방법 |
| EP1978807B1 (en) * | 2006-01-30 | 2016-03-23 | Panion & BF Biotech Inc. | Method of treating chronic kidney disease |
| KR20140016438A (ko) * | 2009-07-21 | 2014-02-07 | 케릭스 바이오파마슈티컬스 인코포레이티드 | 구연산철 투여형태 |
| JP5827326B2 (ja) * | 2010-07-07 | 2015-12-02 | アーデリクス，インコーポレーテッド | リン酸輸送を阻害する化合物及び方法 |
| PL3730136T3 (pl) * | 2012-06-21 | 2024-03-25 | Keryx Biopharmaceuticals, Inc. | Zastosowanie cytrynianu żelaza(iii) w leczeniu pacjentów z przewlekłą chorobą nerek |
-
2014
- 2014-11-03 EP EP20173867.1A patent/EP3747432A1/en active Pending
- 2014-11-03 JP JP2016552432A patent/JP2016535780A/ja active Pending
- 2014-11-03 HK HK16111332.6A patent/HK1223031A1/zh unknown
- 2014-11-03 EP EP14858106.9A patent/EP3065734A4/en not_active Ceased
- 2014-11-03 EA EA201690926A patent/EA201690926A1/ru unknown
- 2014-11-03 AU AU2014341975A patent/AU2014341975A1/en not_active Abandoned
- 2014-11-03 KR KR1020167014000A patent/KR102392441B1/ko active Active
- 2014-11-03 SG SG11201603091QA patent/SG11201603091QA/en unknown
- 2014-11-03 CN CN201480072217.1A patent/CN105873583A/zh active Pending
- 2014-11-03 CA CA2928200A patent/CA2928200A1/en not_active Abandoned
- 2014-11-03 US US15/031,678 patent/US20160256486A1/en not_active Abandoned
- 2014-11-03 BR BR112016009901A patent/BR112016009901A8/pt not_active Application Discontinuation
- 2014-11-03 WO PCT/US2014/063643 patent/WO2015066593A1/en not_active Ceased
- 2014-11-04 TW TW103138244A patent/TWI744215B/zh active
- 2014-11-04 TW TW110136784A patent/TW202203910A/zh unknown
-
2015
- 2015-01-29 MX MX2016005734A patent/MX2016005734A/es unknown
-
2016
- 2016-04-27 IL IL245317A patent/IL245317A0/en unknown
-
2018
- 2018-12-11 US US16/216,772 patent/US20190307791A1/en not_active Abandoned
-
2019
- 2019-07-31 JP JP2019140640A patent/JP6828100B2/ja active Active
-
2021
- 2021-01-20 JP JP2021007091A patent/JP2021073230A/ja active Pending
-
2024
- 2024-12-31 US US19/006,830 patent/US20250360167A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016535780A5 (enExample) | ||
| Balakumar et al. | Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared? | |
| AR089862A1 (es) | USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA | |
| JP2016519107A5 (enExample) | ||
| JP2016516751A5 (enExample) | ||
| HRP20201069T1 (hr) | Primjena tasimelteona pod uvjetima natašte | |
| JP2015522603A5 (enExample) | ||
| JP2014513121A5 (enExample) | ||
| JP2013523758A5 (enExample) | ||
| De Caridi et al. | Effectiveness of prostaglandin E1 in patients with mixed arterial and venous ulcers of the lower limbs | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| JP2017061488A5 (enExample) | ||
| MX2018011293A (es) | Composicion farmaceutica de liberacion prolongada que comprende cisteamina o sal de la misma. | |
| Félix et al. | Warfarin-induced gastric intramural hematoma | |
| Send et al. | Multiple causes for rhinolithiasis | |
| WO2018051295A3 (en) | Non-saponifiable compounds of natural lipids for use in the treatment of tumour pathologies | |
| Pinero-Saavedra | DRESS syndrome in an elderly patient: case report | |
| Glezer et al. | Decrease in heart rate in patients with coronary artery disease and chronic heart failure the purpose and means | |
| JP2019529554A5 (enExample) | ||
| WO2018051294A3 (en) | Non—saponifiable compounds of natural lipids for use in the treatment of cardiac pathologies | |
| Protasov et al. | The effectiveness of moxonidine in patients with uncomplicated hypertensive crisis | |
| JP2019504085A5 (enExample) | ||
| Sahu et al. | Ondansetron causing near fatal catastrophe in a renal transplant recipient | |
| Adamyan et al. | Spironolacton reduces left ventricular diastolic stiffness, remodeling and improves functional status in hypertensive patients with preserved ejection fraction heart failure | |
| Torihashi | Warfarin/heparin |